摘要
目的探讨程序性死亡受体-1(PD-1)、程序性死亡配体-1/2(PD-L1/2)在初诊多发性骨髓瘤(NDMM)患者骨髓T细胞亚群和骨髓瘤细胞中的表达水平及其与临床特征的关系。方法收集22例NDMM患者及18例健康对照组骨髓及临床资料,利用流式细胞术分选CD4^(+)、CD8^(+)T细胞及骨髓瘤细胞,观察PD-1、PD-L1/2的表达水平。结果NDMM组CD8^(+)T细胞水平较对照组明显升高,CD4^(+)/CD8^(+)比值较对照组明显降低(均P<0.05);NDMM组CD4^(+)T细胞PD-1和PD-L2表达水平较对照组明显升高(均P<0.05);T细胞亚群与骨髓瘤细胞中PD-1、PD-L1/2水平与NDMM患者性别、年龄、免疫分型、Durie-Salmon分期亚型、ISS分期及mSMART 3.0分层差异无统计学意义(均P>0.05)。结论MM常伴有免疫功能失调,可能与表达PD-1及PD-L1/2的T淋巴细胞和肿瘤细胞之间相互免疫抑制作用有关。
Objective To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma(NDMM)patients and their relation with clinical features.Methods We collected the bone marrow and clinical data of 22 NDMM patients and 18 cases of healthy controls.We sorted CD4^(+)T cells,CD8^(+)T cells and myeloma cells by flow cytometry,and observed the expression of PD-1 and PD-L1/2.Results Compared with the control group,the proportion of CD8^(+)T cells in the NDMM group was significantly higher,while the ratio of CD4^(+)/CD8^(+)was significantly lower(both P<0.05).The expression levels of PD-1 and PD-L2 in CD4^(+)T cells in the NDMM group were significantly higher than those in the control group(both P<0.05).The expression levels of PD-1,PD-L1 and PD-L2 in T cell subsets and myeloma cells of NDMM patients were not correlated with the gender,age,immune typing,Durie-Salmon stage and subtypes,ISS stage or mSMART3.0 stratification(both P>0.05).Conclusion Most of MM patients suffering immune abnormality,which may be associated with the mutual immunosuppressive effects between T lymphocytes and plasma cells which expressing PD-1 and PD-L1/2.
作者
马银娟
杨柯
杨夏影
摆姣凤
白海
吴涛
付丽华
姜俊峰
潘耀柱
MA Yinjuan;YANG Ke;YANG Xiaying;BAI Jiaofeng;BAI Hai;WU Tao;FU Lihua;JIANG Junfeng;PAN Yaozhu(Department of Hematology,The 940th Hospital of Joint Support Force of Chinese People’s Liberation Army,Lanzhou 730050,China;Graduate School of Ningxia Medical University,Yinchuan 750004,China;Department of Hematology,Gansu Provincial Cancer Hospital,Lanzhou 730050,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第1期40-45,共6页
Cancer Research on Prevention and Treatment
基金
甘肃省卫生行业科研计划项目(GSWSKY-2019-63)
军队后勤应用基础研究项目(CLB19J047)。
